Building a mechanistic mathematical model of hepatitis C virus entry by Mphatso Kalemera (6476033)

“…We conduct experiments to thoroughly quantify the influence of an increase or decrease in receptor availability upon the extent of viral entry. …”

Table_1_Associations among past trauma, post-displacement stressors, and mental health outcomes in Rohingya refugees in Bangladesh: A secondary cross-sectional analysis.pdf by Haley Ritsema (14431125)

“…Trauma (OR = 4.98, 95% CI = 2.20–11.31, p < 0.001) was associated with increased odds of PTSD. Living in a household that received income was associated with decreased odds of PTSD (OR = 0.74, 95% CI = 0.55–1.00, p = 0.05).…”

The effect of iNOS inhibition on the observed increase in caspase-3 activity post-proteasomal blocking. by Karl A. Dunne (430633)

Image4_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image6_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image3_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table2_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.DOCX by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image1_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table4_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image2_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image7_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image5_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table3_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table1_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

The mediating effect of body mass index on the relationship between smoking and hip or knee replacement due to primary osteoarthritis. A population-based cohort study (the HUNT Stu... by Marianne Bakke Johnsen (4723974)

“…We identified 1322 THRs and 754 TKRs. For men, the total effect of current vs. never smoking revealed a decreased risk of THR (HR 0.59, 95% CI 0.46–0.76) and TKR (HR 0.47, 95% CI 0.32–0.66). …”

Data Sheet 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

A hypothesis-driven <i>in vitro</i> genetic screen of <i>S</i>. <i>aureus</i> mutants to identify genes required for propagation through nanopores. by Elysia A. Masters (9553742)

“…WT USA300 is plotted as the positive control (grey bar) and mutant pools are indicated by colors matching panel A. Of the 24 mutants screened, only <i>agrC</i>, <i>sasC</i> and <i>pbp4</i> displayed a significantly decreased propagation efficiency compared to 100% propagation efficiency of WT USA300 <i>S</i>. …”

Data Sheet 1_Comparison of percutaneous vs. cutdown access for endovascular aortic repair in the treatment of type B aortic dissection: a meta-analysis.pdf by Zhongyou Liang (22617608)

“…In comparison to CEVAR, PEVAR resulted in a reduced hospital length of stay (MD = −2.16 days, 95% CI: −3.05 to −1.27, P < 0.00001), decreased operative time (MD = −40.87 min, 95% CI: −49.72 to −32.02, P < 0.00001), shorter postoperative duration (MD = −1.01 days, 95% CI: −1.56 to −0.45, P = 0.0004), diminished incidence of groin infection (OR = 0.44, 95% CI: 0.30 to 0.65, P < 0.0001), lower occurrence of heart-related complications (OR = 0.76, 95% CI: 0.59 to 1.00, P = 0.05), and reduced incidence of lymphocele (OR = 0.49, 95% CI: 0.24 to 0.98, P = 0.04), but a higher incidence of surgical suture failure (OR = 2.61, 95% CI: 1.52 to 4.50, P = 0.0005) and pseudoaneurysm (OR = 2.64, 95% CI: 1.09 to 6.41, P = 0.03). …”

Table_1_Facial nerve outcome score: a new score to predict long-term facial nerve function after vestibular schwannoma surgery.docx by Giuseppe Di Perna (10305336)

“…The totality of patients with FNOS grade A showed an HB value < 3 at 12 months, decreasing to 70% for those with FNOS grade B, whereas 100% of patients with FNOS grade C showed an HB value ≥ 3. …”

Data Sheet 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”